Stay updated on Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.

Latest updates to the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe study was terminated after a prespecified futility analysis following enrollment of the first cohort of 10 patients. The page now shows Terminated and removes the Active, not recruiting status, with related date updates.SummaryDifference0.6%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision indicator in the page footer now shows v3.3.2 instead of v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedRemoval of the government funding and operating status notice banner. This change does not alter any study data, eligibility criteria, enrollment details, or contact information on the page.SummaryDifference0.4%

- Check41 days agoChange DetectedMinor formatting adjustments and a slightly updated last-updated timestamp are visible; core study content such as title, objectives, eligibility criteria, locations, and schedule appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference3%

- Check76 days agoChange DetectedMajor update: expanded immune biology terminology and a version upgrade to v3.1.0, replacing v3.0.2.SummaryDifference0.9%

Stay in the know with updates to Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Plus Ipilimumab in Renal Medullary Carcinoma Clinical Trial page.